Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting
DALLAS, February 1, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced a presentation at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2024 Event taking place virtually on Saturday, February 3rd, Details for the presentation are as follows:
Session Title: Emerging Therapies for Non-Exudative AMD
Title: Optogenetics for Restoring Vision in Geographic Atrophy Secondary to Advanced AMD
Session Date: February 3, 2024
Session Time: 11:30 AM, EST
Presenter: Allen C. Ho, MD
During his presentation, Dr. Ho will showcase preclinical results suggesting geographic atrophy from advanced AMD may be amenable to treatment with non-viral, laser-targeted multi-characteristic opsin (MCO) optogenetic therapy, and the potential for clinical translation of Nanoscope’s MCO-020.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.